Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Molecular Cancer Therapeutics 6, 318-325, January 1, 2007. doi: 10.1158/1535-7163.MCT-06-0299
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cazales, M.
Right arrow Articles by Ducommun, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cazales, M.
Right arrow Articles by Ducommun, B.

Research Articles: Therapeutics, Targets, and Development

Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly

Martine Cazales1, Rose Boutros1, Marie-Christine Brezak2, Sophie Chaumeron2, Grégoire Prevost2 and Bernard Ducommun1

1 LBCMCP-CNRS UMR5088-IFR109, Université Paul Sabatier, Toulouse, France and 2 IPSEN, Institut Henri Beaufour, Les Ulis, France

Requests for reprints: Bernard Ducommun, LBCMCP-CNRS UMR5088-IFR109, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse, France. Phone: 33-56155-6210; Fax: 33-56155-8109. E-mail: ducommun{at}cict.fr.

Abstract

The CDC25 cell cycle regulators are promising targets for new pharmacologic approaches in cancer therapy. Inhibitory compounds such as BN82685 have proven to be effective in specifically targeting CDC25 in cultured cells and in inhibiting tumor cell growth. Here, we report that BN82685 impairs microtubule dynamic instability and alters microtubule organization and assembly at the centrosome in interphase cells. Treatment of mitotic cells with BN82685 delays mitotic spindle assembly, chromosome capture, and metaphase plate formation. Furthermore, we show that combining low concentrations of both BN82685 and paclitaxel inhibits the proliferation of HT29 human colon cancer cells. Our results show a role for CDC25 phosphatases in regulating microtubule dynamics throughout the cell cycle and suggest that combinations of CDC25 inhibitors with microtubule-targeting agents may be of therapeutic value. [Mol Cancer Ther 2007;6(1):318–25]


Footnotes

Grant support: Centre National de la Recherche Scientifique, l'Université Paul Sabatier and la Ligue Nationale Contre le Cancer (Equipe labellisée 2005) to B. Ducommun.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 5/22/06; revised 10/ 6/06; accepted 11/17/06.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. Boutros, V. Lobjois, and B. Ducommun
CDC25B Involvement in the Centrosome Duplication Cycle and in Microtubule Nucleation
Cancer Res., December 15, 2007; 67(24): 11557 - 11564.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.